Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters : A single-center analysis.

Müjdat YildirimJens Müller von der GrünRia WinkelmannEmmanouil FokasFranz RödelHanns AckermannClaus RödelPanagiotis Balermpas

Published in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2017)

The combined p16- and p53-expression status in cervical metastases of CUP may represent a simple method for risk stratification. Further validation of these biomarkers in large prospective trials is essential to design rational trials for CUP treatment optimization.

Keyphrases

poor prognosis
binding protein
long non coding rna
replacement therapy